Citation Information :
Nagvekar V, Shah A, Unadkat VP, Chavan A, Kohli R, Hodgar S, Ashpalia A, Patil N, Kamble R. Clinical Outcome of Patients on Ceftazidime–Avibactam and Combination Therapy in Carbapenem-resistant Enterobacteriaceae. Indian J Crit Care Med 2021; 25 (7):780-784.
Introduction: Carbapenem-resistant Enterobacteriaceae (CRE) infections have a major effect on mortality as well as healthcare cost. Intensive care units (ICUs) in India, the epicenters for multidrug-resistant organisms, are facing a “postantibiotic era” because of very limited treatment options. A latest beta-lactam/beta-lactamase inhibitor ceftazidime–avibactam (CZA) new has a broad-spectrum antibacterial activity. CZA inhibits class-A and class-C beta-lactamases (as well Klebsiella pneumoniaecarbapenemase (KPC)), along with some class-D carbapenems such as OXA-48-like enzymes that are seen in Enterobacteriaceae has recently become available. The current study aimed to assess and present the clinical response and patient outcome with infections due to CRE when treated with CZA alone or in combination with other drugs.
Materials and methods: This retrospective study reviews the experience recorded and analyzed at two tertiary care centers including only adult patients with CRE infection who had received CZA alone or in combination with other antibiotics over a period between February 2019 and January 2020.
Results: In the period from February 2019 to January 2020, 119 culture-confirmed CRE isolates were tested for Xpert Carba-R. The predominant genetic mechanism was a combination of NDM+OXA-48 in 45/119 (37.81%). Total 40/57 patients received CZA+aztreonam alone or in combination with other drugs with an overall cure rate of 77.5% while the rest 17 received CZA alone in combination with the cure rate of 82.35%. 41/57 (71.92%) patients were in ICU.
Conclusion: With overall mortality of 21%, these data suggest that CZA is a viable option for patients with CRE infections. To our knowledge, this is the first Indian study reporting CZA data in CRE infections.
Escandon-Vargas K, Reyes S, Gutierrez S, Villegas MV. The epidemiology of carbapenemases in Latin America and the Caribbean. Expert Rev Anti-Infect Ther 2017;15(3):277–297. DOI: 10.1080/14787210.2017.1268918.
Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 2012;18(1):54–60. DOI: 10.1111/j.1469-0691.2011.03478.x.
Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29(12):1099–1106. DOI: 10.1086/592412.
Wattal C, Javeri Y, Goel N, Dhar D, Saxena S, Singh S, et al. Convergence of minds: for better patient outcome in intensive care unit infections. Indian J Crit Care Med 2017;21(3):154–159. DOI: 10.4103/ijccm.IJCCM_365_16.
Calfee DP. Recent advances in the understanding and management of Klebsiella pneumoniae. F1000Res 2017;6:1760. DOI: 10.12688/f1000research.11532.1.
Shankar C, Nabarro LE, Anandan S, Ravi R, Babu P, Munusamy E, et al. Extremely high mortality rates in patients with carbapenem-resistant, hypermucoviscous Klebsiella pneumoniae blood stream infections. J Assoc Phys India 2018;66:13.
Gomez-Simmonds A, Nelson B, Eiras DP, Loo A, Jenkins SG, Whittier S, et al. Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2016;60:3601–3607. DOI: 10.1128/AAC.03007-15.
Van Duin D, Bonomo RA. Ceftazidime–Avibactam and ceftolozane/Tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis 2016;63:234–241. DOI: 10.1093/cid/ciw243.
Kazmierczak KM, Bradford PA, Stone GG, de Jonge BL, Sahm DF. In vitro activity of ceftazidime–avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the international network for optimal resistance monitoring (INFORM) global surveillance program from 2012 to 2015. Antimicrob Agents Chemother 2018;62:e00592-18. DOI: 10.1128/AAC.00592-18.
Karlowsky JA, Biedenbach DJ, Kazmierczak KM, Stone GG, Sahm DF. Activity of ceftazidime–avibactam against extended-spectrum- and AmpC β-lactamase-producing Enterobacteriaceae collected in the INFORM global surveillance study from 2012 to 2014. Antimicrob Agents Chemother 2016;60:2849–2857. DOI: 10.1128/AAC.02286-15.
Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, et al. Results from the China antimicrobial surveillance network (CHINET) in 2017 of the in vitro activities of ceftazidime–avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2019;63:e02431-18. DOI: 10.1128/AAC.02431-18.
Karaiskos I, Galani I, Souli M, Giamarellou H. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant gram-negative pathogens. Expert Opin Drug Metab Toxicol 2019;15:133–149. DOI: 10.1080/17425255.2019.
Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ 2016;353:i1585. DOI: 10.1136/bmj.i1585.
Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime–avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016;63:1615–1618. DOI: 10.1093/cid/ciw636.
Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, et al. Efficacy of ceftazidime–avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis 2019;68(3):355–364. DOI: 10.1093/cid/ciy492.
Van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Colistin versus ceftazidime–avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 2018;66(2):163–171. DOI: 10.1093/cid/cix783.
Sousa A, Perez-Rodriguez MT, Soto A, Rodriguez L, Perez-Landeiro A, Martinez-Lamas L, et al. Effectiveness of ceftazidime–avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 2018;73(11):3170–3175. DOI: 10.1093/jac/dky295.
Alraddadi BM, Saeedi M, Qutub M, Alshukairi A, Hassanien A, Wali G. Efficacy of ceftazidime–avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae. BMC Infect Dis 2019;19:772. DOI: 10.1186/s12879-019-4409-1.
King M, Heil E, Kuriakose S, Bias T, Huang V, El-Beyrouty C, et al. Multicenter study of outcomes with ceftazidime–avibactam in patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother 2017;61:e00449-17. DOI: 10.1128/AAC.00449-17.